Efficacy of once‐weekly insulin efsitora versus once‐daily basal insulin in type 2 diabetes: A systematic review and meta‐analysis
Authors' conclusion
Once-weekly insulin efsitora demonstrated comparable glycaemic efficacy and superiority in reduction of HbA1c and change in total weekly insulin dose at 52 weeks, while maintaining an acceptable safety profile. Longer-term studies and real-world data are warranted to further confirm sustained efficacy, safety, and cost-effectiveness.
Study context
- Population
- Adults with T2D; Randomized Controlled Trials (RCTs) from PubMed, Embase and Scopus up to July 6, 20257 RCTs, 4170 analysed
- Participants
- 2,347 vs 1,877
- Comparison
- Once-weekly insulin efsitora vs once-daily basal insulin
- Efsitoran = 2,347
- Once-daily insulinn = 1,877reference
- Outcome
- Change in HbA1c, change in FPG, change in total weekly insulin dose, and HbA1c target achievement
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
HbA1c reduction · 26 weeks
MD
−0.02 %
CI −0.11 to 0.08
P = 0.74
Between Efsitora and Once-daily insulin
MD −0.02 % (CI −0.11 to 0.08); P = 0.74
As reported in the abstract
Further pooled results
| Outcome | MD (%) (CI) | P value | |
|---|---|---|---|
| HbA1c change · 52 weeksGreater reduction with efsitora | −0.12 (−0.20 to −0.03) | P = 0.009 | |
| −0.3−0.2−0.100.1Difference, % (linear scale) |
| Outcome | MD (CI) | P value | |
|---|---|---|---|
| Change in total weekly insulin dose · 52 weeksLower change with efsitora | −30.55 (−46.48 to −14.52) | P = 0.0002 | |
| −60−40−20020Difference (linear scale) |
TIR
- Non-significant numerical increase in time in target glucose range
- MD 1.72 (95% CI −0.10 to 3.53; p = 0.06)
TAR
- Time above range decreased
- MD −2.13 (95% CI −4.01 to −0.25; p = 0.03)
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Major adverse eventsNumerically, non-significant increase with efsitora | 1.22 (0.97–1.53) | P = 0.09 | |
| 0.512Odds ratio (log scale) |
Hypoglycaemia, serious adverse events, injection-site reactions, hypersensitivity
- Comparable across groups
Original publication
Efficacy of once‐weekly insulin efsitora versus once‐daily basal insulin in type 2 diabetes: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 19 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →